Pulmonary Squamous Cell Carcinoma following Head and Neck Squamous Cell Carcinoma: Metastasis or Second Primary?

Geurts, Tom W.; Nederlof, Petra M.; Brekel, M.W.M. van den; Veer, Laura J. van’t; Jong, Daphne de; Hart, A.A.M.; Zandwijk, Nico van; Klomp, Houke M.; Balm, Alfons J. M.; Velthuysen, Marie‐Louise F. van

doi:10.1158/1078-0432.ccr-05-0257

Cited by 86 publications

(72 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DNA isolation was performed conform standard methods. 18 DNA isolated from the tumor as well as normal (not tumor) tissue obtained from a separate tissue block was amplified and analyzed for 12 …”

Section: Loss Of Heterozygosity Detectionmentioning

confidence: 99%

“…Because there is no standard or validated procedure to interpret LOH patterns in sarcoma, we developed a dedicated decision tree model based on the clonality information from the translocation data and according to similar methods as developed for other tumor types in our group (Figure 1). 18 …”

Section: Strategy Of Analysis Of Clonalitymentioning

confidence: 99%

“…18 LOH analysis is easy to perform on paraffin embedded tissue and, thus, potentially very useful in everyday clinical practice, as well as for the analysis of retrospective series. However, whether this method is also suitable for liposarcoma has not been explored so far.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Multifocal Myxoid Liposarcoma—Metastasis or Second Primary Tumor?

Vreeze

Jong

Nederlof

et al. 2010

The Journal of Molecular Diagnostics

Self Cite

View full text Add to dashboard Cite

The classification of multifocal myxoid/round cell liposarcoma, which is defined as tumor presentation in at least two separate sites before manifestation in the lungs, as either metastasis or as a second primary tumor, has essential clinical consequences. Genetically, myxoid/round cell liposarcoma is characterized by t(12; 16)(q13;p11) or t(12;22)(q13;q12), and various exon fusion transcripts are described with varying incidences, which permits their use as markers for clonality. Moreover, in solid tumors, analysis of loss of heterozygozity is valuable for clonality analysis. Therefore, fifteen multifocal myxoid/round cell liposarcoma patients with two to five metachronous (n ‫؍‬ 12) or synchronous (n ‫؍‬ 3) localizations were investigated. Using RT-PCR, the detailed molecular characteristics of the FUS-CHOP and EWS-CHOP breakpoints were determined. Loss of heterozygozity analysis at twelve loci was then used to further analyze clonal relationships. In all patients, tumor sites showed identical FUS-CHOP fusion products. In six patients, identical rare fusion transcripts were found, supporting a clonal relationship. Nine patients had the common exon5-FUS/exon2-CHOP fusion transcript, and two of these were identified as clonally related by loss of heterozygozity analysis. In all other patients, loss of heterozygozity analysis was highly suggestive of a clonal relationship, and no evidence for interpretation of a second primary tumor was found. This study supports the metastatic nature of apparent multifocal myxoid/round cell liposarcoma. Multifocal presentation in soft tissue tumors, especially in myxoid/round cell liposarcoma (MRLS), has been a matter of debate for some time. This issue has not been fully resolved because of the limited patients for whom data are available.1-5 Multifocality in soft tissue sarcoma is defined as the presence of sarcoma on at least two separate sites before manifestation of disease in sites where sarcomas most commonly metastasize, in particular the lungs. The first reported case of multifocal sarcoma dates to 1934, when Siegmund described a patient with multiple fatty tumors, which was interpreted as "Lipoblastische Sarcomatose" or a systemic malignant disease of the soft tissue.6 Since then, the debate persists whether this entity represents separate primary tumors or an unusual pattern of metastasis.Differentiation between second primary and disseminated MRLS has major clinical consequences. A resectable second primary MRLS would indicate an optimal surgical approach combined with (neo) adjuvant radiotherapy with curative intent, whereas in metastatic disease, the choice of treatment, surgery, radiotherapy, or chemotherapy is made with a limited expectation of ultimate cure, predicting other metastases in the near future.A clonal relationship between two tumors proves their common origin in case of metastases. Conversely, the absence of a clonal relationship would suggest a second primary sarcoma. Several assays have been developed to evaluate clonal relationship between tumors....

show abstract

Section: Loss Of Heterozygosity Detectionmentioning

confidence: 99%

Section: Strategy Of Analysis Of Clonalitymentioning

confidence: 99%

See 1 more Smart Citation

Multifocal Myxoid Liposarcoma—Metastasis or Second Primary Tumor?

Vreeze

Jong

Nederlof

et al. 2010

The Journal of Molecular Diagnostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients treated for head and neck carcinoma frequently develop second primary tumors in the lung (17). The risk of second primary lung cancer in this group of patients is 14-47%.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Second Primary Lung Cancers Developed Following Different System Tumors

Özdilekcan¹,

Turanlı²,

Songür³

et al. 2013

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETAmaç: Bu çalışmada farklı sistem malignitelerine sekonder olarak gelişen akciğer tümörlerin klinik özellikleri ve primer tümörle olan ilişkilerinin araştırılması amaçlandı. Yöntemler: 2002-2010 yılları arasında takipleri sırasında ikinci primer kanser tanısı alan otuz hasta çalışmaya dahil edildi. Hastalar, akciğer kanseri gelişme sürelerine göre senkron (n: 7 hasta, %16.7) ve metakron (n: 23 hasta, %83.3) grup olarak iki grupta değerlendirildi. Bulgular: Hastaların %50'sinde ilk 2.5 yıl içinde ikinci primer kanser saptandı. Hastaların çoğunluğunun (%43.3) akrabalarında ekstra pulmoner kanser öyküsü vardı. Akciğer kanseri tanısı konulan hastalardan %50'sinde sigarayı bırakma, %30'unda aktif içici ve %20'sinde hiç sigara kullanmamış olma öyküsü vardı. Primer kanser ile ilgili yapılan tedaviye yanıt ve ikincil gelişen kanserin süresi arasında istatistiksel olarak anlamlı bir ilişki saptanmadı (p=0.36).Grupların tamamında sağ kalım süresi 24 ay senkron grupta, 12 ay metakron grupta belirlendi. Sonuç: Primer hastalıktan sonra özellikle ilk 2.5 yıl içinde yakın takip ve hastalara sigara içiciliğinin bıraktırılmasının teşvik edilmesi önem taşımaktadır. Anahtar Kelimeler: Akciğer kanseri; ikinci primer; senkron; metakron ABSTRACT Objectıve: This study aimed to investigate clinical characteristics and prognosis of secondarily developed lung tumors in the cases having different system malignancy and to evaluate the relationship with the primary tumor. Methods: Between January 2002-December 2010 thirty patients diagnosed as second primary lung cancer have been included in the study. The patients were grouped according to lung cancer development time; synchronous group (n: 7 patients, 16.7%) and metachronous group (n: 23 patients, 83.3%). Results: Second cancer was detected in 50% of the patients within the first 2.5 years. Majority of patients had extra pulmonary cancer history concerning their relatives (43.3%). The rate of quitting smoking among all patients before the diagnosis of lung cancer was 50%, current smoker rate was 30% and never smoker was 20%. There was no statistical relationship between the response to treatment of first cancer and the duration of cancer developed secondarily (p=0.36). The overall survival of groups was found 24 months (95% confidence interval: 18.3 months) and 12 months (95% confidence interval: 10-14 months) respectively for synchronous and metachronous groups. Conclusıon: Close follow-up on pulmonary system especially within the first 2.5 years after primary disease and encouragement on quitting smoking is important.

show abstract

“…For example, in the case of enteric differentiation in primary adenocarcinoma of the lungs, it may be hard to distinguish from colorectal carcinoma metastasis (35).…”

Section: Challenges In Diagnosismentioning

confidence: 99%

Does Cell Type in Lung Cancer Have any Clinical Importance?

Yüksel¹

2018

Eur J Ther

View full text Add to dashboard Cite

Lung cancer is the leading cause of deaths from cancer in men (20%), and it has reached 16.5% and started to surpass deaths due to breast cancer in women. Lung tumors include many subtypes according to the classification of the World Health Organization. These tumors are primarily classified as small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) from the aspects of disease presentation, potential of metastasis, clinical presentation, response to treatment and survival time. NSCLC constitutes nearly 80-85% of all lung cancers. NSCLCs are classified in different subtypes. The two predominant NSCLC histological subtypes are adenocarcinoma and squamous cell carcinoma. Adenocarcinomas have become the most commonly seen subtype of lung cancers (40%). The incidence of Squamous cell carcinoma has decreased in the last few decades and it is estimated to constitute 20-30% of all lung cancers today. Subtypes of NSCLC develop due to different factors, exhibit different clinical and radiological presentations, and consequently respond differently to surgical treatment and chemotherapeutic agents.

show abstract

Pulmonary Squamous Cell Carcinoma following Head and Neck Squamous Cell Carcinoma: Metastasis or Second Primary?

Cited by 86 publications

References 27 publications

Multifocal Myxoid Liposarcoma—Metastasis or Second Primary Tumor?

Multifocal Myxoid Liposarcoma—Metastasis or Second Primary Tumor?

Analysis of Second Primary Lung Cancers Developed Following Different System Tumors

Does Cell Type in Lung Cancer Have any Clinical Importance?

Contact Info

Product

Resources

About